The Latest Breaking News on Pharma

Insider Q&A: FDA official on vaping's "promise or peril"

The new chief at the Food and Drug Administration's tobacco center has inherited a raft of problems

The Independent UK · Sep 26, 2022

Pfizer seeks to expand omicron booster to 5- to 11-year-olds

Pfizer is asking the Food and Drug Administration to expand use of its updated COVID-19 booster shot to children ages 5 to 11

The Independent UK · Sep 26, 2022

Commentary: Prevent a legal Catch-22 that could push thousands of generic drugs off the market

Carvedilol could be the poster child for how to lower drug prices. Since 2007, more than 20 million patients with cardiovascular conditions have enjoyed generic versions of the popular beta-blocker, which cost 2 cents a dose compared with $4.81 for the brand-name product. Patents on the drug Coreg, dating back…

Los Angeles Times · Sep 26, 2022

Advocates seek more say in how opioid settlements are spent

As billions of dollars in opioid lawsuit settlements are starting to flow to governments, families and advocates impacted by the opioid crisis are pushing for a meaningful say in how the money will be used

The Independent UK · Sep 23, 2022

1 Biotech Stock That Has Fallen Hard in 2022

Biotech stock Timber Pharmaceuticals (TMBR) is down more than 70% year-to-date. Analysts expect it to keep reporting losses over the next two years. So, will it be wise to buy the stock now? Read on to learn our view….

StockNews.com · Sep 23, 2022

Suspected drug deaths in first six months of year 22 per cent lower than last year

The number of suspected drug deaths in Scotland in the first six months of this year has dropped by 22 compared to last year.

The National (Scotland) · Sep 23, 2022

Pharma Giants Moderna And Novavax Trend Lower In This Pattern: What's Going On?

Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards.

Benzinga · Sep 23, 2022

1 Stock Under $65 That You Shouldn't Ignore

Leading biopharmaceutical company Gilead Sciences (GILD) reported impressive sales in the last quarter and raised its full-year 2022 guidance. Furthermore, the company’s strategic acquisitions, drug approvals, and research breakthroughs should drive its growth in the coming quarters. Given GILD’s discounted valuation, we think it could be wise to buy this…

StockNews.com · Sep 23, 2022

FDA reminds people not to cook chicken in Nyquil after ‘dangerous’ social media trend resurfaces

‘These video challenges, which often target youths, can harm people — and even cause death,’ the agency said

The Independent UK · Sep 23, 2022

4.4M Americans roll up sleeves for omicron-targeted boosters

More than 4 million Americans have rolled up their sleeves for the new omicron-specific booster shots

The Independent UK · Sep 23, 2022